AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05472181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS (Repetitive TMS)
Description: TMS stimulation produce electromagnetic pulses that can directly changes the neural firing in the brain. The rTMS applies the magnetic pulses in a repetitive manner, and can induce either an inhibitory or excitatory effect on cortical neurons. In this study we use high frequency rTMS (10 Hz) to provide the excitatory effect.
Study NCT05472181 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Speech training
Description: The behavioural training will include reading sentences in which a syllable is spoken in time to a rhythmic beat.
Study NCT05472181 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech training
Description: The behavioural training will include reading sentences in which a syllable is spoken in time to a rhythmic beat.
Study NCT05240924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention
Description: ERP is a specialized cognitive behavioral intervention conducted over the course of 8-16 therapy sessions. ERP is based upon exposure principles and the idea that people can habituate to the distress caused by OCD triggers and learn to cope with anxiety about feared consequences without engaging in compulsive behaviors to 'neutralize' the obsession. ERP begins with psychoeducation about OCD and exposure, followed by construction of a hierarchy, or list, of situations that are feared, avoided, or trigger OCD rituals such as washing or checking. Then, the therapist and client begin in-session exposures to hierarchy items utilizing response or ritual prevention techniques to avoid reinforcing the ritual. Exposures can be in vivo, such as touching a contaminated item, or imaginal, such as visualizing a feared consequence happening.
Study NCT05240924 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stress Management Training
Description: The stress management training intervention will be based on that delivered by Simpson in an ERP trial. It will be delivered by PhD and Master's level therapists from each site's clinics. The stress management training intervention will begin with an introductory session providing psychoeducation about OCD, followed by 15 sessions covering stress management skills such as deep breathing progressive muscle relaxation, positive imagery, assertiveness training, and problem solving. Each session will contain an extended practice of the selected skill and will end with homework assignments to practice the stress management skills and monitor symptoms.
Study NCT06500000 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: liquid chromatography-mass spectrometry (LC/MS)
Description: Metabolomics is a rapidly evolving high-throughput technology that allows the measurement of the entire complement of metabolites generated by biochemical reactions under certain conditions in biological fluids or tissues. This technology has been used extensively to identify biomarkers in various cancers, nervous system diseases, cardiovascular diseases, pituitary diseases, and other diseases. The identification of biomarkers can be clinically useful for a more accurate diagnosis, prognosis, and treatment choice as well as disease monitoring. Among mass spectrometry (MS) methods, liquid chromatography- mass spectrometry (LC-MS) has been recognized as a robust metabolomics tool and has been widely applied in metabolite identification and quantification due to its high sensitivity, peak resolution, and reproducibility.
Study NCT06570239 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intervention group
Description: Protocol A combines dry physiotherapy and psychological support. It will be organised on an outpatient basis. Weeks 1, 2 and 3: 8 sessions of dry physiotherapy and 3 sessions of psychotherapy. 5 psychotherapy sessions will be given over the following five weeks.~Protocol B combines hydro-physiotherapy and hydro-thermal treatments with psychological support. Protocol B begins with 3 weeks in a spa establishment - Care provided during weeks 1, 2 and 3: 8 hydrokinesitherapy sessions, 32 hydrothermal treatments, 3 psychotherapy sessions. 5 psychology sessions will be given over the following five weeks.
Study NCT06570239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intervention group
Description: Protocol A combines dry physiotherapy and psychological support. It will be organised on an outpatient basis. Weeks 1, 2 and 3: 8 sessions of dry physiotherapy and 3 sessions of psychotherapy. 5 psychotherapy sessions will be given over the following five weeks.~Protocol B combines hydro-physiotherapy and hydro-thermal treatments with psychological support. Protocol B begins with 3 weeks in a spa establishment - Care provided during weeks 1, 2 and 3: 8 hydrokinesitherapy sessions, 32 hydrothermal treatments, 3 psychotherapy sessions. 5 psychology sessions will be given over the following five weeks.
Study NCT05186181 — intervention group
Intervention type: BEHAVIORAL
Intervention: In situ fenestration
Description: Interventional therapy of aortic dissection. In situ needle fenestration of left subclavian artery.
Study NCT05878366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Seasonal Malaria Chemoprophylaxis (under 5 year old) implemented by the MoH without DOT
Description: Standard approach for SMC strategy used by the Ministry of Health (without directly-observed therapy) and without any interference of the study team. Implemented over 4 rounds, carried out in June-October 2023 with \~30 days between rounds.
Study NCT05878366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seasonal Malaria Chemoprophylaxis (under 5 years old) with DOT
Description: SMC will be implemented with the same number of rounds and the same timing as in active comparator arm but village health workers will visit the participants at home to administer each dose of study treatment (with DOT-directly-observed therapy)
Study NCT05878366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seasonal Malaria Chemoprophylaxis (under 10 years old) with DOT
Description: SMC will be implemented as in arm 2 but age of participants is extended up to 10 years: each dose of study treatment (with DOT-directly-observed therapy) distributed at home by village health workers.
Study NCT05131178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ON-Q Pump® with continuous infusion of bupivacaine
Description: 270 ml of 0.5 % bupivacaine. The device being used is a fixed flow pump meaning the rate of 2 mL/hour. The pump is connected to the catheter and left in place for up to 4 post-operative days or until the completion of the infusion.
Study NCT05131178 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ON-Q Pump® with continuous infusion of saline
Description: 270 mL of normal saline. The device being used is a fixed flow pump meaning the rate of 2 mL/hour. The pump is connected to the catheter and left in place for up to 4 post-operative days or until the completion of the infusion.
Study NCT05652374 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ialuril 50ml Prefill
Description: 50ml of sterile Ialuril (HA 1.6% CS 2%) bladder instillations weekly for 6 weeks, followed by monthly maintenance therapy for 6 months
Study NCT05652374 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nitrofurantoin
Description: nitrofurantoin 100mg daily (1dd100mg or 2dd50mg) for 6 months. ( In case of resistance/intolerance/allergy for nitrofurantoin alternatively trimethoprim 100mg daily)
Study NCT04742465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented reality technological assistance for the movements of people with Alzheimer's disease or MCI in a controlled environment.
Description: Augmented reality technological assistance for the movements of people with Alzheimer's disease or MCI in a controlled environment.~The ARIADE project will take place in a controlled and reproducible ecological environment (Ker Lann gymnasium) and will aim at assessing the effectiveness of Augmented Reality assistance, that of the devices for detecting wandering, the safety of the patient when traveling with an Augmented Reality headset, and his acceptance of the device.~Three routes each comprising seven intersections, i.e. a location requiring a decision on navigation, will allow us in 20 patients to objectively compare the three different visual aids offered in augmented reality, i.e. arrows, light path, animated companion.
Study NCT05022004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide ophthalmic suspension
Description: dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks
Study NCT05022004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azopt®
Description: dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks
Study NCT05780853 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tablet Game-based Assessment - YARN assessment service
Description: Tablet game-based assessment to assess neurodevelopmental profile.
Study NCT05780853 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Adaptive Behavior Assessment System, Third Edition (ABAS-3)
Description: A parent-reported child behavioural assessment questionnaire used to diagnose and classify various developmental, learning and behavioural disabilities and disorders.
Study NCT05780853 — intervention group
Intervention type: OTHER
Intervention: Demographic questionnaire
Description: Parent/carer and child's demographic data such as age, ethnicity, employment status, household income, medical history and education status.
Study NCT04614545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine 37.5 Mg
Description: Patients will receive 37.5 mg of phentermine daily for a 12 week duration
Study NCT04614545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine 37.5 Mg
Description: Patients will receive 37.5 mg of phentermine daily for a 12 week duration
Study NCT04614545 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary program
Description: Patients will be able to select either the Mediterranean diet or the Ketogenic diet and will work with a dietician
Study NCT04614545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary program
Description: Patients will be able to select either the Mediterranean diet or the Ketogenic diet and will work with a dietician
Study NCT04614545 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: Patients will be provided with a personalized exercise program
Study NCT04614545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Patients will be provided with a personalized exercise program
Study NCT05641831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo peripheral blood collection
Study NCT05641831 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo peripheral blood collection
Study NCT05641831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow biopsy and aspiration
Study NCT05641831 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow biopsy and aspiration
Study NCT05641831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Given SC
Study NCT05641831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Radiography
Description: Undergo chest x-ray
Study NCT05641831 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Chest Radiography
Description: Undergo chest x-ray
Study NCT05641831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT05641831 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT05736887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: N-Acetylcysteine in 600mg tablets
Study NCT05736887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in 600mg tablets
Study NCT05641831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given SC
Study NCT05641831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05641831 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05930951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBT076
Description: OBT076 is an ADC constituted by a fully human immunoglobulin 1 (IgG1) antibody directed against the CD205/Ly75 antigen (MBH1309), inducing potent cytotoxic and anti-tumor activity
Study NCT05930951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OBT076
Description: OBT076 is an ADC constituted by a fully human immunoglobulin 1 (IgG1) antibody directed against the CD205/Ly75 antigen (MBH1309), inducing potent cytotoxic and anti-tumor activity
Study NCT05930951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Balstilimab is a human monoclonal antibody that targets programmed cell death protein 1 (PD-1).
Study NCT05489861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M-AM
Description: To examine the effects of affirmation and infant massage taught to their parents on their infants' sleep quality and parent-infant attachment.
Study NCT05489861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: F-AM
Description: To examine the effects of affirmation and infant massage taught to their parents on their infants' sleep quality and parent-infant attachment.
Study NCT05227690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-231 10 mg
Description: CVL-231 10 mg, oral (tablet), once per day for 6 weeks
Study NCT05227690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Required CVL-231 30 mg
Description: CVL-231 30 mg, oral (tablet), once per day for 6 weeks
Study NCT04614662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPARK Symptom Screening Linked to Feedback to Providers
Description: Symptom screening three times weekly via SPARK, feedback of symptoms to healthcare providers and development of care pathways for symptom management.
Study NCT05474859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XT-0528
Description: Once Daily
Study NCT05227690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, oral (tablet), once per day for 6 weeks
Study NCT05436938 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Jing Si herbal tea liquid packets use
Description: with or without Jing Si herbal tea liquid packets use
Study NCT05436938 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Jing Si herbal tea liquid packets use
Description: with or without Jing Si herbal tea liquid packets use
Study NCT05606354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Experimental
Study NCT05606354 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention group
Description: Experimental
Study NCT05462613 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: quality of life questionnaires
Description: EORTC QLQ-C30 questionnaire (Quality of life questionnaire- Cancer 30) CR29 questionnaire (Colo-rectal cancer 29) EQ-5D3L questionnaire (EuroQol-5 Dimensions, 3 levels)
Study NCT05462613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality of life questionnaires
Description: EORTC QLQ-C30 questionnaire (Quality of life questionnaire- Cancer 30) CR29 questionnaire (Colo-rectal cancer 29) EQ-5D3L questionnaire (EuroQol-5 Dimensions, 3 levels)
Study NCT05462613 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: Blood sample for plasma collection Blood sample for ctDNA (circulating tumoral DNA) collection
Study NCT05462613 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample for plasma collection Blood sample for ctDNA (circulating tumoral DNA) collection
Study NCT06001320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir 480 mg once daily
Description: We will test the study hypothesis in a single center, matched (1:1 fashion) pilot study of Letermovir 480 mg once daily versus historically matched AA kidney transplant recipients who received valganciclovir. We will enroll 30 AA patients over a 12-month period into the Letermovir group and compare outcomes to a historical group of 30 AA kidney transplant recipients who have received valganciclovir prophylaxis (1:1 fashion), for a total of 60 patients. We will attempt to match patients on Letermovir to the historical patients who received valganciclovir, based on age, kidney Donor profile index and the presence of panel of reactive antibodies.
Study NCT06001320 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Historical/Control
Description: The control study group will include high-risk African American kidney transplant recipients cared for with Valganciclovir in the 5 years prior to the enrollment start for the study group. This time frame is based upon the current volume of transplants done at VCU. On average 30 liver and/or kidney transplants are done per month. Thus, 5 years should be an adequate time frame to mine enough number of participants to answer our primary research hypothesis.
Study NCT05462613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: - Regorafenib will be administered 3 weeks out of 4 for two months or unacceptable toxicity.~* For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~* For the second cycle: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle.
Study NCT05462613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapies
Description: * Capecitabine: 625mg/m²/orally twice daily continuously during the first two months~* Cyclophosphamide: 50 mg per os, daily, for two months
Study NCT06413615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA022-BB05
Description: Monoclonal antibody-drug conjugate for injection
Study NCT05462613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 75 mg orally and daily during two months
Study NCT05462613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/Kg every 2 weeks according to investigator practice, until disease progression or unacceptable toxicity
Study NCT05462613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/Kg every 2 weeks according to investigator practice, until disease progression or unacceptable toxicity
Study NCT05462613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI or FOLFOX
Description: every 2 weeks according to investigator practice
Study NCT05462613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI or FOLFOX
Description: every 2 weeks according to investigator practice
Study NCT05768139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STX-478
Description: STX-478 is a mutant-selective PI3Kα inhibitor
Study NCT05054933 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ultrasound capsule endoscopy
Description: Healthy volunteers or patients with suspected esophageal disease will be enrolled to take ultrasound capsule endoscopy examination followed by conventional endoscopic ultrasound examination within 2 weeks.
Study NCT05647252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Whole Body and nasal decolonization with octenidin (Octenisan Set)
Description: Octenidin body lotion once a day during the five consecutive days preceding the elective orthopedic surgery, including for the hair.~Octenidin nasal creme 2-3 times a day in both nasal orifices during the same period
Study NCT06047431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706H
Description: QL1706H is the subcutaneousely administered formulation of QL1706, it contains two unique monoclonal antibodies.
Study NCT04921722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Percutaneous sirolimus
Description: We compare topical and oral use of sirolimus in the treatment of superficial complicted vascular anomalies. In experimental group, we administrate percutaneous sirolimus. Drop 5 ml of sirolimus oral solution and 5 g of dressing into the mixed bottle. Apply mixed gel of topical sirolimus to affected area. Use it twice a day for 6 months.
Study NCT04921722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral sirolimus
Description: We compare topical and oral use of sirolimus in the treatment of superficial complicted vascular anomalies. In active comparator group, we administrate oral sirolimus. Oral dose of sirolimus is calculated according to body surface area. Take it twice a day for 6 months. Maintain the blood concentration of sirolimus at 5-15ng/ml.
Study NCT04691323 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HU-Go app
Description: A novel multifunctional mobile app (HU-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
Study NCT04885244 — intervention group
Intervention type: PROCEDURE
Intervention: Index or spine revision surgery for complex adult spinal deformity
Description: Surgical interventions will be patient specified by treating surgeon.